Retatrutide is the compound posting the biggest weight loss numbers anyone has reported in a GLP-1-class trial. It gets talked about as the next step beyond tirzepatide, and on the trial data, that framing holds up. But it's also still investigational, not approved, and only available through clinical trials, so the gap between the hype and what you can actually get is wide. Here is the full picture: what it is, how it works, what the Phase 3 program actually found, how it's dosed in trials, and where the honest line sits between proven and unproven.
What is retatrutide?
Retatrutide is a synthetic, once-weekly injectable peptide built to act on three hormone pathways at once. Where semaglutide hits one receptor and tirzepatide hits two, retatrutide adds a third. It is a single molecule that activates the body's receptors for GLP-1, GIP, and glucagon, which is why it gets called a triple hormone receptor agonist. The first two pathways drive the appetite-suppressing effect that the whole GLP-1 class is known for. The third, glucagon, is the one that sets retatrutide apart.
How it works
The GLP-1 and GIP components do what people expect from this class: they reduce appetite and slow how fast the stomach empties, so the main thing a person feels is eating less without fighting cravings all day. The glucagon component is the addition that matters. Activating the glucagon receptor is associated with increased energy expenditure and fat oxidation, meaning the body leans toward burning more energy rather than only taking in less. So retatrutide is working two sides of the equation at the same time: lowering intake through appetite suppression and nudging output up through the glucagon pathway. That dual action is the leading explanation for why its weight loss numbers run higher than the single- and dual-agonist compounds before it.
The evidence
This is where retatrutide has moved fast, and where the honest framing matters most. The early Phase 2 data (published in the New England Journal of Medicine) showed up to about 24% mean weight loss at 48 weeks, which was already a standout number. The Phase 3 program, called TRIUMPH, has since reported considerably larger results.
In TRIUMPH-1, the first registrational Phase 3 obesity trial, participants on the 12 mg weekly dose lost an average of 28.3% of their body weight (about 70 lbs) over 80 weeks, and 45.3% of participants achieved at least 30% weight loss, a level historically associated with bariatric surgery. Participants with a starting BMI of 35 or higher who continued into a study extension lost up to an average of 30.3% (about 85 lbs) at 104 weeks. Lower doses still produced large effects: the 9 mg arm landed around 26%, and even the 4 mg dose, reached with a single escalation step, produced roughly 19% at 80 weeks with a discontinuation rate lower than placebo.
Other trials in the program have reinforced the picture across different populations. TRIUMPH-4, in participants with obesity and knee osteoarthritis, reported 28.7% weight loss at 68 weeks on 12 mg, alongside significant reductions in osteoarthritis pain. A type 2 diabetes trial reported a smaller but still substantial 16.8% at 40 weeks, which fits the general pattern that weight loss tends to run lower in diabetic populations across this entire drug class.
The honest boundary: despite all of this, retatrutide is still investigational and is not approved for obesity. The TRIUMPH program spans multiple trials with more readouts expected through 2026, and the regulatory picture is still being built. Every bit of legitimate access is through a clinical trial. Anyone presenting it as an approved or settled option is ahead of where the evidence and the regulators actually are.
Dosing (research reference)
In the Phase 3 trials, retatrutide is given as a once-weekly subcutaneous injection, titrated upward over time rather than started at full dose. The trial structure built up every four weeks starting from 2 mg, with the tested target doses being 4 mg, 9 mg, and 12 mg. A 4 mg maintenance arm is also under evaluation as a possible step-down once primary weight loss is achieved.
The pattern across the data is a clear dose-response: more weight loss at higher doses, but also more gastrointestinal side effects and higher dropout at 12 mg than at 9 mg. That tradeoff between maximum effect and tolerability is the central dosing consideration for this compound.
Timeline
Like the rest of the GLP-1 class, retatrutide is not a fast compound. The trial endpoints sit at 68 to 80 weeks, and the largest results in the extension data came at 104 weeks. Appetite effects show up early, within the first couple of weeks, but the headline weight loss figures are the product of more than a year of continuous use with gradual dose escalation. It is a long-horizon tool, not a quick fix.
Side effects
The side-effect profile is dominated by gastrointestinal events, the same family seen across the GLP-1 class: nausea, and related GI complaints, worst during dose increases. What distinguishes retatrutide is intensity rather than kind. It runs the highest GI adverse-event rates of the major compounds in its class, and the 12 mg dose shows higher discontinuation than 9 mg specifically because of tolerability. Across the program, the overall safety profile has been described as consistent with other incretin-based therapies, driven primarily by those GI effects rather than by anything novel.
Where it fits
Retatrutide is the high-ceiling option of the GLP-1 class, the one chasing the largest possible weight loss, and the trial data backs that positioning. But the catch is unavoidable: it is investigational, accessible only through trials, and carries the highest GI burden of the group along with less long-term safety data than the approved compounds. The reasonable read is that retatrutide is the most powerful weight loss compound in this class on the numbers, and simultaneously the one with the least settled regulatory and safety footing. Both things are true at once, and any honest discussion of it has to hold both.